Results 181 to 190 of about 25,024 (228)
Some of the next articles are maybe not open access.
Expert Opinion on Pharmacotherapy, 2008
Paroxetine is a widely used antidepressant that has received attention regarding suicide risk in younger patients.The purpose of this paper is to review the pharmacology, efficacy and safety of paroxetine in the affective disorders.The authors performed a PubMed search for all literature in English crossing the words 'paroxetine' and 'Paxil' against ...
Siu Wa, Tang, Daiga, Helmeste
+5 more sources
Paroxetine is a widely used antidepressant that has received attention regarding suicide risk in younger patients.The purpose of this paper is to review the pharmacology, efficacy and safety of paroxetine in the affective disorders.The authors performed a PubMed search for all literature in English crossing the words 'paroxetine' and 'Paxil' against ...
Siu Wa, Tang, Daiga, Helmeste
+5 more sources
Pharmacopsychiatry, 1997
The authors report a case of galactorrhea following antidepressant treatment where paroxetine might be responsible. Paroxetine is a selective serotonergic reuptake inhibitor (SSRI). Galactorrhea occasionally is a dopamine-mediated side effect observed with neuroleptic drugs.
B, Bonin +3 more
openaire +2 more sources
The authors report a case of galactorrhea following antidepressant treatment where paroxetine might be responsible. Paroxetine is a selective serotonergic reuptake inhibitor (SSRI). Galactorrhea occasionally is a dopamine-mediated side effect observed with neuroleptic drugs.
B, Bonin +3 more
openaire +2 more sources
2013
Paroxetine hydrochloride (3S-trans)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-piperidine hydrochloride (or (-)-(3S,4R)-(4-(p-fluorophenyl)-3-[[3,4-(methylenedioxy)-phenoxy]methyl]piperidine hydrochloride), a phenylpiperidine derivative, is a selective serotonin reuptake inhibitor.
David, Germann +3 more
openaire +2 more sources
Paroxetine hydrochloride (3S-trans)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-piperidine hydrochloride (or (-)-(3S,4R)-(4-(p-fluorophenyl)-3-[[3,4-(methylenedioxy)-phenoxy]methyl]piperidine hydrochloride), a phenylpiperidine derivative, is a selective serotonin reuptake inhibitor.
David, Germann +3 more
openaire +2 more sources
Paroxetine and the electroencephalogram
Journal of Psychopharmacology, 1987Electroencephalograms, recorded before and after 4 weeks' treatment with parox etine or placebo, were assessed blind to patient, treatment and treatment interval. No signifi cant differences were found between the paroxetine and the placebo groups.
E M, Sedgwick, J, Cilasun, J G, Edwards
openaire +2 more sources
Current Medical Research and Opinion, 2003
This review of paroxetine is based on Medline and PsycLit searches and a manual search of the available research literature. It aims to cover the pharmacology of this frequently prescribed SSRI antidepressant in terms of its indications, efficacy and adverse effects.
openaire +2 more sources
This review of paroxetine is based on Medline and PsycLit searches and a manual search of the available research literature. It aims to cover the pharmacology of this frequently prescribed SSRI antidepressant in terms of its indications, efficacy and adverse effects.
openaire +2 more sources
International Clinical Psychopharmacology, 1992
Paroxetine has been characterized as a highly potent and selective 5-hydroxytryptamine (serotonin) reuptake inhibitor. This selectivity has been demonstrated not only for monoamine uptake mechanisms but also for neurotransmitter receptor systems. The pharmacokinetic studies indicate that paroxetine may be administered once a day, and that on this ...
openaire +2 more sources
Paroxetine has been characterized as a highly potent and selective 5-hydroxytryptamine (serotonin) reuptake inhibitor. This selectivity has been demonstrated not only for monoamine uptake mechanisms but also for neurotransmitter receptor systems. The pharmacokinetic studies indicate that paroxetine may be administered once a day, and that on this ...
openaire +2 more sources
Journal of the American Academy of Child & Adolescent Psychiatry, 2004
On June 19, 2003 the U.S. Food and Drug Administration (FDA) released a statement regarding the antidepressant Paxil® for pediatric depression. The primary reason for the statement was new data indicating a possible increased risk of suicidal thinking and suicidal attempts in children and adolescents under the age of 18 treated with the drug Paxil for ...
openaire +2 more sources
On June 19, 2003 the U.S. Food and Drug Administration (FDA) released a statement regarding the antidepressant Paxil® for pediatric depression. The primary reason for the statement was new data indicating a possible increased risk of suicidal thinking and suicidal attempts in children and adolescents under the age of 18 treated with the drug Paxil for ...
openaire +2 more sources